Company intelligence / Profile preview
Vanda Pharmaceuticals Inc.
Washington, Washington D.C., United States of Americavandapharmaceuticalsinc.gcs-web.com ↗
- Ownership
- Public · VNDA
- Employees
- ~368
- Development stage
- Commercial
01
Overview
Vanda has two FDA-approved products: HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone) for schizophrenia. The company reported $267.7 million in revenue for 2024, with HETLIOZ generating $166.3 million and Fanapt generating $98.4 million. They have submitted an NDA for Bysanti for acute bipolar I disorder and schizophrenia, and are developing tradipitant for gastroparesis (received a Complete Response Letter from FDA).
- Therapeutic areas
- GastroenterologyPsychiatryHematologyRare DiseasesNeurology
- Modalities
- Small moleculesantisense oligonucleotides
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →03
Partnerships
AnaptysBio (for imsidolimab)Novartis (previously for Fanapt)
04
Financials
- Market cap
- $315.7M
- Total revenue
- $50.5M
- Enterprise value
- $168.5M
Beyond the preview
Go deeper on Vanda Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vanda Pharmaceuticals Inc..